Convergent Genomics, Inc.

Convergent Genomics is a genomic diagnostics company developing non-invasive urine-based tests for urologic cancer detection and monitoring. Their flagship product UroAmp uses next-generation sequencing and machine learning to detect urothelial cancer earlier and with greater accuracy than standard imaging. The company serves urologists and oncologists seeking to personalize cancer care through actionable genomic insights.